6-((2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl)amino)-N-(4-(trifluoromethyl)phenyl)heptanamide | 83086-14-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-((2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl)amino)-N-(4-(trifluoromethyl)phenyl)heptanamide
• 英文别名: 6-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]-N-[4-(trifluoromethyl)phenyl]heptanamide
• CAS: 83086-14-0
• 化学式: C₂₂H₂₇F₃N₂O₄
• 分子量: 440.463
• InChiKey: ZRBLJEGNAJFUPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  102
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5-乙酰基戊酸 在 platinum(IV) oxide N-甲基吗啉 、 氢气 、 溶剂黄146 、 氯甲酸异丁酯 作用下， -15.0~25.0 ℃ 、101.33 kPa 条件下， 反应 0.25h， 生成 6-((2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl)amino)-N-(4-(trifluoromethyl)phenyl)heptanamide
  参考文献：
  名称：

  儿茶酚胺的缀合物。1.与异丙肾上腺素有关的N-烷基官能化的羧酸同类物和酰胺。

  摘要：

  合成了一系列官能化的儿茶酚胺（同类物），其中形式上，异丙肾上腺素的N-异丙基已被长度可变的直链烷基链延长，并被羧基或取代的酰胺封端。通常通过将去甲肾上腺素与酮酸或预先形成的酮酰胺还原胺化来制备化合物。在短链衍生物的情况下，通过酰胺环容易地环合成内酰胺，模型酰胺衍生物的替代合成涉及羧酸同系物的活化和与胺的偶合。这些化合物作为潜在的β-肾上腺素能激动剂的体外评估表明，尽管羧酸同类物的功效相对较低，模型酰胺衍生物的效力高度依赖于烷基链的长度以及酰胺上取代基的性质。通常，芳族酰胺是最有效的，尽管芳族基团上取代基的性质和位置会极大地影响其效力。讨论了这些研究的意义，包括一般的β-肾上腺素药物设计以及羧酸同类物与载体的连接。

  DOI：

  10.1021/jm00358a007

文献信息

• PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE
  申请人：Wainer Irving W.

  公开号：US20120157543A1

  公开（公告）日：2012-06-21

  This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.

  本公开涉及(R,R)-和(R,S)-芬特罗类似物的发现，它们在结合β2-肾上腺素受体方面具有高度有效性。提供了这些类似物的示例化学结构。还提供了包括所披露的(R,R)-芬特罗和芬特罗类似物的制药组合物，以及使用这些化合物和组合物治疗心脏疾病，如充血性心力衰竭和肺部疾病，如哮喘或慢性阻塞性肺疾病的方法。
• Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10562843B2

  公开（公告）日：2020-02-18

  This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.

  本公开涉及(R,R)-和(R,S)-非诺特罗类似物的发现，这些类似物能非常有效地结合β2-肾上腺素能受体。本文提供了这些类似物的示例性化学结构。还提供了包括所公开的(R,R)-非诺特罗和非诺特罗类似物的药物组合物，以及使用此类化合物和组合物治疗充血性心力衰竭等心脏疾病和哮喘或慢性阻塞性肺病等肺部疾病的方法。
• PREPARATION OF (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE
  申请人：The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

  公开号：EP2064174B1

  公开（公告）日：2016-10-26
• PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Serv

  公开号：US20170081276A1

  公开（公告）日：2017-03-23

  This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.
• US9522871B2
  申请人：——

  公开号：US9522871B2

  公开（公告）日：2016-12-20